# Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk

Study · id `cardio:ct-nct02313584` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02313584](<https://clinicaltrials.gov/study/NCT02313584>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02313584

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 464 participants.

## Technical summary

Registry record NCT02313584. Randomized; no masking; primary purpose prevention. Start 2014-12 (registry gives no type); primary completion 2016-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 464 participants (planned count; ClinicalTrials.gov record NCT02313584, source copy `cardio:ctgov-nct02313584-2014-12-10`, retrieved 2026-10-26)
- Start date: 2014-12 (registry gives no type) (ClinicalTrials.gov record NCT02313584, source copy `cardio:ctgov-nct02313584-2014-12-10`, retrieved 2026-10-26)
- Primary completion: 2016-09 (anticipated) (ClinicalTrials.gov record NCT02313584, source copy `cardio:ctgov-nct02313584-2014-12-10`, retrieved 2026-10-26)
- Completion: 2017-09 (anticipated) (ClinicalTrials.gov record NCT02313584, source copy `cardio:ctgov-nct02313584-2014-12-10`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02313584-2014-12-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk
- Condition: Atrial Fibrillation
- Condition: Thromboembolism
- Intervention (Drug): dabigatran
- Intervention (Drug): placebo
- Lead sponsor: Korea University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Dabigatran (`cardio:dabigatran`)
- Registry lists this organization as the lead sponsor: Korea University (`cardio:org-korea-university`)

## Provenance

Content hash: c6f8538bab5998b0adc80d3fe3ed5a1cc17870654b179dd70651b3d857b1ef57
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
